Revolutionary Team Award 3 - exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer
Altered lipid metabolism is an androgen- and obesity-regulated process in prostate tumour cells that can be used as a source of biomarkers in (i) patients with low-volume localised disease to predict, at the time of diagnosis, whether an individual patient has indolent or aggressive disease; and (ii) patients with high-risk localised prostate cancer to detect clinical responses to androgen receptor (AR) targeting therapies in neoadjuvant and adjuvant clinical trials.
The aims of the program are:
- To define signatures of lipid profiles that are correlated with prostate cancer aggressiveness and response to androgen targeted therapy.
-
To investigate the effects of androgens and obesity on lipid metabolism in prostate cancer.
-
To convert prostate lipid profiles into non-invasive detection modalities.
Investigators
| Lisa Butler | University of Adelaide |
| Wayne Tilley | University of Adelaide |
| Andrew Hoy | University of Sydney |
| Gary Wittert | University of Adelaide |
| Colleen Nelson | APCRC-Q, IHBI, QUT, TRI |
| Andrew Scott | Ludwig Cancer Institute, Melbourne |
| John Swinnen | University of Sydney |
| Andrew Weickhardt | Warringal Private Hospital |
| Ian Davis | Monash University |
| Carl Power | University of New South Wales |
| Tina Bianco-Miotto | University of Adelaide |
| Pamela Russell | APCRC-Q, IHBI, QUT, TRI |
| David Brooks | Imperial College London, England |
| Peter Sutherland | Royal Adelaide Hospital |
| Francis Parnis | Adelaide Cancer Centre |
Administering Institution
University of Adelaide
Duration
2015 - 2018
Funding
| PCFA Movember Revolutionary Team Award | $3 250 000 |
